The cancer hypothesis of pulmonary arterial hypertension: the next ten years.
作者信息
Condon David, Agarwal Stuti, Chakraborty Ananya, de Jesus Perez Vinicio A
机构信息
Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, California.
The Vera Moulton Wall Center for Pulmonary Vascular Medicine, Stanford University Medical Center, Stanford, California.
出版信息
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1138-L1139. doi: 10.1152/ajplung.00057.2020. Epub 2020 Mar 18.
Abstract
摘要
相似文献
1
The cancer hypothesis of pulmonary arterial hypertension: the next ten years.肺动脉高压的癌症假说：未来十年
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1138-L1139. doi: 10.1152/ajplung.00057.2020. Epub 2020 Mar 18.
2
Assessing the cancer hypothesis of pulmonary arterial hypertension: the devil is in the detail.评估肺动脉高压的癌症假说：细节决定成败。
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1140-L1141. doi: 10.1152/ajplung.00084.2020. Epub 2020 Mar 18.
3
Multilevel omics: A next step on the way to understanding pulmonary arterial hypertension?多组学：通往理解肺动脉高压之路的下一步？
Thorax. 2019 Apr;74(4):317-318. doi: 10.1136/thoraxjnl-2018-212840. Epub 2019 Jan 24.
4
Decoding the Link Between Inflammation and Pulmonary Arterial Hypertension.解读炎症与肺动脉高压之间的联系
Circulation. 2022 Sep 27;146(13):1023-1025. doi: 10.1161/CIRCULATIONAHA.122.059949. Epub 2022 Sep 26.
5
Deconstructing the Melting Pot in Pulmonary Arterial Hypertension.剖析肺动脉高压中的大熔炉现象
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1329-1331. doi: 10.1164/rccm.202001-0156ED.
6
Risk scores as a surrogate in pulmonary arterial hypertension: a different lens - Authors' reply.肺动脉高压中作为替代指标的风险评分：另一种视角——作者回复
Lancet Respir Med. 2024 Mar;12(3):e11. doi: 10.1016/S2213-2600(24)00002-X.
7
The updated cancer paradigm of PAH: recognizing complexity.PAH的更新癌症范式：认识到复杂性。
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1111-L1114. doi: 10.1152/ajplung.00159.2020. Epub 2020 Apr 22.
8
Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension.为肺动脉高压中肺血管阻力难题增添了重要一环。
Eur Respir J. 2020 Jul 9;56(1). doi: 10.1183/13993003.00962-2020. Print 2020 Jul.
9
Checkpoint Kinase 1 Promotes the Development of Pulmonary Arterial Hypertension.关卡激酶1促进肺动脉高压的发展。
Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1504-1506. doi: 10.1161/ATVBAHA.119.312969. Epub 2019 Jul 24.
10
Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.肺血管阻力在肺动脉高压患者中的临床应用
J Cardiothorac Surg. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4.
引用本文的文献
1
Single-Cell and Spatial Transcriptomics Identified Fatty Acid-Binding Proteins Controlling Endothelial Glycolytic and Arterial Programming in Pulmonary Hypertension.单细胞和空间转录组学鉴定出控制肺动脉高压中内皮糖酵解和动脉编程的脂肪酸结合蛋白
Arterioscler Thromb Vasc Biol. 2025 May 22. doi: 10.1161/ATVBAHA.124.321173.
2
Glycolysis modulation: New therapeutic strategies to improve pulmonary hypertension (Review).糖酵解调节：改善肺动脉高压的新治疗策略（综述）。
Int J Mol Med. 2024 Dec;54(6). doi: 10.3892/ijmm.2024.5439. Epub 2024 Oct 18.
3
Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.苏根/低氧诱导的大鼠肺动脉高压的生物学和药理学的最新概述。
J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):241-283. doi: 10.1089/jamp.2024.0016.
4
Single-cell and Spatial Transcriptomics Identified Fatty Acid-binding Proteins Controlling Endothelial Glycolytic and Arterial Programming in Pulmonary Hypertension.单细胞和空间转录组学鉴定出控制肺动脉高压中内皮糖酵解和动脉编程的脂肪酸结合蛋白
bioRxiv. 2024 Apr 15:2024.02.11.579846. doi: 10.1101/2024.02.11.579846.
5
Autonomic nervous modulation: early treatment for pulmonary artery hypertension.自主神经调节：肺动脉高压的早期治疗。
ESC Heart Fail. 2024 Apr;11(2):619-627. doi: 10.1002/ehf2.14616. Epub 2023 Dec 18.
本文引用的文献
1
The hallmarks of severe pulmonary arterial hypertension: the cancer hypothesis-ten years later.严重肺动脉高压的特征：癌症假说十年后。
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1115-L1130. doi: 10.1152/ajplung.00476.2019. Epub 2020 Feb 5.
2
Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension.利用机器学习在肺动脉高压中发现不同的免疫表型。
Circ Res. 2019 Mar 15;124(6):904-919. doi: 10.1161/CIRCRESAHA.118.313911.
3
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again.药物重新定位用于治疗肺动脉高压：旧药新用
J Am Heart Assoc. 2019 Jan 8;8(1):e011343. doi: 10.1161/JAHA.118.011343.
4
A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.赞成与反对观点辩论：2017 年美国胸科学会国际会议上关于肺动脉高压发病机制的当前争议。
Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315(4):L502-L516. doi: 10.1152/ajplung.00150.2018. Epub 2018 Jun 7.
5
Emerging therapeutics in pulmonary hypertension.肺动脉高压的新兴治疗方法。
Am J Physiol Lung Cell Mol Physiol. 2018 May 1;314(5):L769-L781. doi: 10.1152/ajplung.00259.2017. Epub 2018 Feb 1.
6
PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics.PVDOMICS：一项通过表型组学改善肺血管疾病理解的多中心研究。
Circ Res. 2017 Oct 27;121(10):1136-1139. doi: 10.1161/CIRCRESAHA.117.311737.
7
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients.抑制丙酮酸脱氢酶激酶可改善遗传易感患者的肺动脉高压。
Sci Transl Med. 2017 Oct 25;9(413). doi: 10.1126/scitranslmed.aao4583.
8
Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.将肺动脉高压研究转化为改善患者护理
Am J Respir Crit Care Med. 2017 Mar 1;195(5):583-595. doi: 10.1164/rccm.201607-1515PP.
9
Hallmarks of cancer: the next generation.癌症的特征：下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
10
The hallmarks of cancer.癌症的特征
Cell. 2000 Jan 7;100(1):57-70. doi: 10.1016/s0092-8674(00)81683-9.
Zotero 插件